Press Releases

Creative Biogene Develops Custom Lentivirus Services to Support Stable Cell Line Generation

Microbiosci Releases LPS Extraction Service to Support Managing Endotoxins Issues

Creative Biogene Delivers Knockout Mouse Models to Support Gene Editing and Future Studies

Nanoparticle Development Services for Drug Delivery System Research

Acylation Reagents for Gas Chromatography and Other Instrumental Analytical Methods

ExoQuali Products and Protocols Released by Creative Bioarray to Easy Exosome Isolation Process

Histobiolab Provides Over 150 Fish Probes to Satisfy Precise Biological Research Needs

Creative Bioarray Provides 3D Cell Patterning Service Based to Speed up Drug Screening

Press Release: Terumo Pharmaceutical Solutions expands CDMO services outside Japan for global market

Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of injection, primary container, and infusion therapy devices, has today announced it will expand its contract development and manufacturing services for parenteral drugs to global customers.

Elligo Health Research® Named One of Central Texas’ Fastest-Growing Companies

Alfa Chemistry Announces Offering of Low Molecular Weight Carboxylic Acids

Samsung Biologics Reports Third Quarter 2022 Financial Results

Samsung Biologics a leading contract development and manufacturing organization, released today its fiscal year 2022 third-quarter financial results.

Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset

Ardigen has announced that it is supporting the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) Consortium with its technology and expertise

CD Formulation: One-Stop Pharmaceutical Formulation Solution Makes Drug Development Faster, Easier and More Cost-Effective

Andelyn Biosciences announces opening of its state-of-the-art GMP manufacturing facility to meet industry demand

Contact information Eric Blair, Chief Commercial Officer Eric.Blair@AndelynBio.com For media enquiries, please contact Imogen Quail, PR Manager, imogen.quail@ramarketingpr.com, ramarketingpr.com About Andelyn Biosciences, Inc. Andelyn is a biopharmaceutical CDMO Pioneering Solutions That Turn Hope into Reality™. Headquartered in the greater Columbus, Ohio, USA area, Andelyn’s capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP drug substance manufacturing up to 2000L, and drug product manufacturing services. Having 20+ years of experience in viral vector manufacturing, Andelyn offers its clients direct access to globally recognized thought leaders that have enabled 75+ worldwide clinical trials. With the experience gained from over 400 cGMP clinical batches and 2000+ research-grade productions, Andelyn provides its clients with end-to-end manufacturing services, advanced quality systems, full regulatory support, and supply chain vertical integration. Andelyn began operations in its state-of-the-art 200,000 sq. ft. commercial manufacturing facility in September 2022, expanding capacity across 14+ production suites for customization of new programs and tech transferred programs. Andelyn is one of a few select CDMOs that offer clinical through commercial-scale capabilities that will help fulfil Andelyn’s mission of accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients. Andelyn is owned and supported by Nationwide Children’s Hospital (NCH) and Pall-Cytiva, part of Danaher Corporation. For more information, visit: https://andelynbio.com/.

GenNext Technologies Earns the Coveted $250,000 Grand Prize Award at the 2022 BioTools Innovator Final Competition

GenNext Technologies, Inc. has announced that it received the 2022 Grand Prize Award in the BioTools Innovator competition.

EDMOND DE ROTHSCHILD EQUITY STRATEGIES IV acquires a majority stake in ONCODESIGN SERVICES

Oncodesign Services and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, from its main shareholders.

Inizio commits to helping limit the impact of climate change and achieving SBTi Net-Zero Standard

Inizio commits to Science Based Targets initiative

CD BioGlyco Constructures a Glycoengineered P. pastoris Expression System for Research Use

ValiRx signs IP license agreement with Kings College London to progress triple negative breast cancer treatment